Skip to lesson
OncoGuideeducationDiana’s wiki
THE EDUCATION LIBRARY

TNBC recurrence: timing and sites

In one sentence

Recurrence patterns describe when and where triple-negative breast cancer returns in a defined group after treatment.

The intuition

Picture a map with a clock attached. The map tells you where events were found; the clock tells you when they became detectable. Neither tells you what will happen to one person. First ask who was included and how they were treated.

Triple-negative breast cancer (TNBC) is a receptor-defined category. Published groups differ in stage, treatment and response.

How it works

A recurrence is cancer returning after treatment. Cells that persisted can later grow enough to become detectable. Local recurrence involves the original breast area or chest wall; regional recurrence involves nearby lymph nodes; distant recurrence involves other organs. A separate new breast cancer is a second primary, which needs to be distinguished from recurrence. [1]

Timing describes a group, with a specified starting point. In Dent's historical Toronto cohort, 180 of 1,601 patients diagnosed in 1987–1997 had TNBC. Distant-recurrence risk in that subgroup peaked at approximately three years from diagnosis and then declined. This historical pattern supplies neither a modern treatment-specific percentage nor a deadline for possible recurrence. [2]

The group can change as time passes. Reddy's study selected 873 stage I–III patients who had already remained disease-free for five years from diagnosis. Its later-event estimates answer a question about those survivors, rather than everyone at diagnosis. Historical receptor criteria also included some low hormone-receptor positivity. “What happens from diagnosis?” and “What happens after five disease-free years?” have different starting populations. [4]

People enrolledat diagnosis Events during follow-up People disease-freeat the landmark Later eventsin this selected group

Reaching a disease-free landmark changes who is included in the later estimate. It does not erase the need to specify the endpoint and treatment context.

Sites describe another part of the pattern. Breast cancer can recur in bone, lung, liver or brain, among other locations. These are possible sites, not a prediction that each person will develop metastases. [1] In Kennecke's early-stage cohort diagnosed in 1986–1992, basal-like and triple-negative nonbasal groups had distinctive distant-site patterns, including more brain and lung involvement than the luminal A comparison group. Those historical subtype categories and relative patterns do not establish a universal site ranking or today's absolute risks. [3]

Why it matters in cancer

  • Timing helps readers interpret a study's follow-up and survival endpoint. Diagnosis, randomization and surgery are different clocks.
  • Stage, treatment, response and the survival landmark affect whether a published group resembles the group you are asking about.
  • A site's share among recurrences answers “where did the recorded events occur?” To estimate risk among patients, you need that patient denominator and the time/event definition. See the denominator exercise.

Common confusions

  • An early peak is not an individual forecast. A peak identifies when a group's event rate was highest, without supplying one person's next-year probability. [2]
  • Later risk is not zero risk. A disease-free survivor study estimates subsequent events among its selected participants; it cannot guarantee an individual's future. [4]
  • A prominent site does not establish a screening schedule. Describing brain involvement is different from showing that routine brain imaging improves outcomes. NCI's treatment review describes older randomized follow-up trials in which intensive testing of asymptomatic survivors did not improve survival or quality of life. Those findings should not be presented as a test of every newer blood assay or imaging strategy. [5]
  • Detection and benefit are different outcomes. Finding an event earlier does not by itself establish that the earlier detection changes survival. [5]

How it is measured

Studies record confirmed recurrence location/date, a starting date, deaths and loss to follow-up. Ask whether they count first or later sites; one person can have several. The endpoint definition distinguishes raw fractions from estimates accounting for follow-up and competing events. [3, 4]

Try it

A fictional reader finds a study that enrolled only people disease-free five years after diagnosis. Can its later-event estimate be used directly for a newly diagnosed person?

Answer: No. The study has already selected people who reached that landmark without disease. Start by finding evidence with the relevant population, treatment and clock; keep any remaining mismatch visible.

Explain it back: “A recurrence pattern describes ___ in ___, starting from ___; it does not by itself give ___.” One answer: “events / a defined group / a specified date or landmark / an individual's prognosis or a proven screening plan.”

Sources

Source check: October 9, 2026. Historical observational patterns teach how to read timing and location; they are not a calibrated prognosis for a current individual. Expert and learner review remain pending.

References

  1. NCI: breast cancer recurrence, patient definitions and possible sites.
  2. Dent et al., 2007 (PMID 17671126), historical TNBC timing cohort; diagnosis years and population above.
  3. Kennecke et al., 2010 (PMID 20498394), historical early-stage subtype/site study; basal-like and triple-negative nonbasal are distinct study groups.
  4. Reddy et al., 2018, selected five-year disease-free survivors, with historical receptor definitions.
  5. NCI treatment review: posttherapy surveillance, scope and evidence limits of routine follow-up testing.

Used in

Browse the concept index for related learning paths.